These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22757653)

  • 41. Hepatitis B virus genetic diversity.
    Echevarría JM; Avellón A
    J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
    Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
    Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics of lamivudine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences.
    Horiike N; Duong TN; Michitaka K; Joko K; Hiasa Y; Konishi I; Yano M; Onji M
    J Med Virol; 2007 Jul; 79(7):911-8. PubMed ID: 17516520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure.
    Marlet J; Lier C; Roch E; Moreau A; Combe B; Handala L; Lefeuvre S; Maugey M; Elkrief L; d'Alteroche L; Potier P; Brand D; Gaudy-Graffin C
    Antiviral Res; 2021 Aug; 192():105106. PubMed ID: 34214504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A deep-sequencing method detects drug-resistant mutations in the hepatitis B virus in Indonesians.
    Widasari DI; Yano Y; Heriyanto DS; Utsumi T; Yamani LN; Rinonce HT; Wasityastuti W; Lusida MI; Soetjipto ; Okada R; Murakami Y; Tanahashi T; Azuma T; Hayashi Y
    Intervirology; 2014; 57(6):384-92. PubMed ID: 25382636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants.
    Solmone M; Giombini E; Vincenti D; Rozera G; Testa A; Moscetti A; Catalano M; Abbate I; Capobianchi MR; Menzo S
    Antivir Ther; 2014; 19(2):201-9. PubMed ID: 24275042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing.
    Homs M; Buti M; Tabernero D; Quer J; Sanchez A; Corral N; Esteban R; Rodriguez-Frias F
    World J Gastroenterol; 2012 Nov; 18(42):6096-105. PubMed ID: 23155338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pyrosequencing method for sensitive detection of HBV drug resistance mutations.
    Lee GH; Inoue M; Chong RH; Toh J; Wee SY; Loh KS; Lim SG
    J Med Virol; 2018 Jun; 90(6):1071-1079. PubMed ID: 29488627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.
    Beck IA; Payant R; Ngo-Giang-Huong N; Khamduang W; Laomanit L; Jourdain G; Frenkel LM
    J Virol Methods; 2016 Jul; 233():51-5. PubMed ID: 27025356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra‑deep pyrosequencing.
    Chen S; Wu J; Gu E; Shen Y; Wang F; Zhang W
    Mol Med Rep; 2016 Jan; 13(1):651-60. PubMed ID: 26648309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.
    Solmone M; Vincenti D; Prosperi MC; Bruselles A; Ippolito G; Capobianchi MR
    J Virol; 2009 Feb; 83(4):1718-26. PubMed ID: 19073746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-virion sequencing of lamivudine-treated HBV populations reveal population evolution dynamics and demographic history.
    Zhu YO; Aw PPK; de Sessions PF; Hong S; See LX; Hong LZ; Wilm A; Li CH; Hue S; Lim SG; Nagarajan N; Burkholder WF; Hibberd M
    BMC Genomics; 2017 Oct; 18(1):829. PubMed ID: 29078745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
    Rawal RK; Singh US; Chavre SN; Wang J; Sugiyama M; Hung W; Govindarajan R; Korba B; Tanaka Y; Chu CK
    Bioorg Med Chem Lett; 2013 Jan; 23(2):503-6. PubMed ID: 23237841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis B antivirals and resistance.
    Devi U; Locarnini S
    Curr Opin Virol; 2013 Oct; 3(5):495-500. PubMed ID: 24016777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients.
    Ma J; Zhang Y; Chen X; Jin Y; Chen D; Wu Y; Cui J; Wang H; Liu J; Li N; Gao F
    PLoS One; 2013; 8(7):e67606. PubMed ID: 23935839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of hepatitis B virus-mixed genotype infection by ultra deep pyrosequencing in Sudanese patients, 2015-2016.
    Enan KA; Minosse C; El Hussein ARM; Selleri M; Giombini E; Capobianchi MR; Elkhidir IM; Mustafa MO; Khair OM; Hassan DA; Garbuglia AR
    Infection; 2019 Oct; 47(5):793-803. PubMed ID: 30963405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting.
    Lok AS
    Liver Transpl; 2008 Oct; 14 Suppl 2():S8-S14. PubMed ID: 18825720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants.
    Gregori J; Esteban JI; Cubero M; Garcia-Cehic D; Perales C; Casillas R; Alvarez-Tejado M; Rodríguez-Frías F; Guardia J; Domingo E; Quer J
    PLoS One; 2013; 8(12):e83361. PubMed ID: 24391758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads.
    Reuman EC; Margeridon-Thermet S; Caudill HB; Liu T; Borroto-Esoda K; Svarovskaia ES; Holmes SP; Shafer RW
    Bioinformatics; 2010 Dec; 26(23):2929-32. PubMed ID: 20937597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.